Anti-AKT (phospho T308) antibody (ab38449) is a rabbit polyclonal antibody detecting AKT in Western Blot, IHC-P. Suitable for Human, Mouse, Rat.
- Over 770 publications
- Trusted since 2006
View Alternative Names
PKB, RAC, AKT1, RAC-alpha serine/threonine-protein kinase, Protein kinase B, Protein kinase B alpha, Proto-oncogene c-Akt, RAC-PK-alpha, PKB alpha
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT (phospho T308) antibody (AB38449)
Immunohistochemical analysis of AKT (phospho T308) expression in paraffin embedded human lung carcinoma tissue, using ab38449 (1/50). Right-hand panel represents a negative control where ab38449 was pre-incubated with the immunizing (blocking) peptide.
- WB
Supplier Data
Western blot - Anti-AKT (phospho T308) antibody (AB38449)
10% gel.
Running conditions : 60v, 30min; 120v 60min
Transfer conditions : 150mA 120min Nitrocellulose membrane.
Blocking conditions : 5% non-fat milk in TBST, RT, 90min.
Primary antibody incubation : 4℃, overnight
Secondary antibody incubation : room temperature for 45 minutes
Washing condition : 5 ml TBST, 4 x 5min
All lanes:
Western blot - Anti-AKT (phospho T308) antibody (ab38449) at 1/1000 dilution
Lane 1:
HeLa cells at 20 µg
Lane 2:
HeLa cells treated with 0.01 U/mL Insulin for 15 minutes at 20 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG (H+L) HRP at 1/10000 dilution
Predicted band size: 56 kDa
false
- WB
Unknown
Western blot - Anti-AKT (phospho T308) antibody (AB38449)
All lanes:
Western blot - Anti-AKT (phospho T308) antibody (ab38449) at 1/500 dilution
Lane 1:
293 cell lysate - untreated at 30 µg
Lane 2:
293 cell lysate - treated with insulin at 30 µg
Predicted band size: 56 kDa
Observed band size: 56 kDa
false
- WB
CiteAb
Western blot - Anti-AKT (phospho T308) antibody (AB38449)
Western Blotting using Anti-AKT (phospho T308) antibody, ab38449. Publication image from Luo, S. et al., 2019, Exp Mol Med, 30911000. Legend direct from paper.
Effect of luteolin on HBMECs.a The proliferation of HBMECs was assessed in the MTT experiment. The results showed that OGD/R can inhibit their proliferation, while luteolin treatment can promote their proliferation. b, c The apoptosis of HBMECs was assessed by flow cytometry, and the results showed that OGD/R can enhance apoptosis, while apoptosis was downregulated upon luteolin treatment. *P < 0.05, compared with the same time-point in the OGD/R group. d The mRNA of MMP9 was detected by qRT-PCR, and the results showed that luteolin enhances the mRNA of MMP9. *P < 0.05, compared with the OGD/R group. e The protein levels of MMP9 could be suppressed by luteolin. *P < 0.05, compared with the same time-point in the OGD/R group. f The expression levels of PI3K/Akt signaling pathway mRNAs were upregulated and activated by luteolin. *P < 0.05, compared with the same time-point in the OGD/R group. g The protein levels of the PI3K/Akt signaling pathway proteins were upregulated and activated by luteolin. *P < 0.05, compared with the same time-point in the OGD/R group
false
- WB
CiteAb
Western blot - Anti-AKT (phospho T308) antibody (AB38449)
Western Blotting using Anti-AKT (phospho T308) antibody, ab38449. Publication image from Luo, S. et al., 2019, Exp Mol Med, 30911000. Legend direct from paper.
Effect of luteolin on ischemic rats’ brains.a Compared with the DMSO group, the neurologic deficit scores were significantly decreased in the luteolin-M group and luteolin-H group at 24 and 72 h, but no significant differences were found in the luteolin-L group. *P < 0.05, compared with the same time-point in the DMSO group. b, c Compared with the DMSO group, the infarct volume was significantly reduced in the luteolin-M group and luteolin-H group at 24 and 72 h, but no significant differences were found in the luteolin-L group. *P < 0.05, compared with the same time-point in the DMSO group. d The expression levels of MMP9 were suppressed by luteolin in coronal sections around the infarcted area of the brain. *P < 0.05, compared with the same time-point in the DMSO group. e The expression levels of PI3K/Akt signaling pathway-associated proteins were upregulated and activated by luteolin in coronal sections around the infarcted area of the brain. *P < 0.05, compared with the same time-point in the DMSO group
false
Reactivity data
Product details
Anti-AKT (phospho T308) antibody (Anti-RAC antibody; anti-pAKT antibody) (ab38449) has been cited over 779 times in peer reviewed journals and is trusted by the scientific community.
Abcam's high quality validation processes ensure Anti-AKT (phospho T308) antibody (ab38449) has high sensitivity and specificity.
Anti-AKT (phospho T308) antibody (ab38449) has 5 independent reviews from customers.
Anti-AKT (phospho T308) antibody (ab38449) specifically detects AKT Phospho-T308 (UniProt ID: P31749; Molecular weight: 56kDa) and is sold in 100 µg selling sizes.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
AKT influences cell proliferation and apoptosis. As part of a signaling complex AKT phosphorylation modulates several downstream targets important for cell cycle progression and survival. Its activation depends on upstream kinases like PI3K and PDK1 positioning AKT as a central node in cellular responses. By mediating these processes AKT directly impacts organismal growth and stress response mechanisms.
Pathways
AKT is central to the PI3K/AKT/mTOR and insulin signaling pathways both important for cellular metabolism and growth regulation. It interacts with proteins such as mTOR and GSK3 which are involved in cell growth and glycogen synthesis respectively. These interactions show AKT's pivotal role in maintaining cellular energy balance and metabolic processes.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1157)
Recent publications for all applications. Explore the full list and refine your search
Cell death & disease 16:715 PubMed41057302
2025
Applications
Unspecified application
Species
Unspecified reactive species
Diabetology & metabolic syndrome 17:374 PubMed41044623
2025
Applications
Unspecified application
Species
Unspecified reactive species
European journal of histochemistry : EJH 69: PubMed41036671
2025
Applications
Unspecified application
Species
Unspecified reactive species
Global spine journal :21925682251383489 PubMed41001708
2025
Applications
Unspecified application
Species
Unspecified reactive species
PloS one 20:e0333343 PubMed41004429
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in cell and developmental biology 13:1667990 PubMed40970086
2025
Applications
Unspecified application
Species
Unspecified reactive species
PloS one 20:e0332673 PubMed40956826
2025
Applications
Unspecified application
Species
Unspecified reactive species
American journal of translational research 17:6103-6112 PubMed40950323
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of clinical and translational hepatology 13:555-567 PubMed40937080
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in pharmacology 16:1600435 PubMed40918528
2025
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com